76results about "Endocrine organ cells" patented technology

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to increase the expression of NGN3 and NKX6.1 in populations of cells expressing markers characteristic of the pancreatic endocrine lineage.

An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual. The vehicle is particularly well-suited to delivery of insulin from immunoisolated islets of Langerhans, and can also be used advantageously for delivery of high molecular weight products, such as products larger than IgG. A method of making a biocompatible, immunoisolatory implantable vehicle, consisting in a first embodiment of a coextrusion process, and in a second embodiment of a stepwise process. A method for isolating cells within a biocompatible, immunoisolatory implantable vehicle, which protects the isolated cells from attack by the immune system of an individual in whom the vehicle is implanted. A method of providing a needed biological product or metabolic function to an individual, comprising implanting into the individual an immunoisolatory vehicle containing isolated cells which produce the product or provide the metabolic function.

Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and / or purifying definitive endoderm cells are also disclosed.

Compositions and methods are provided for culturing in vitro potentially regenerative cells (PRCs) from which functional tissue-organs are regenerated. In one aspect of the invention, a tissue culture medium is provided which comprises at least 50% of water and a sterol compound that is dissolved in a fatty acid-containing oil at a concentration at least 0.1% by weight based on the weight of the oil and added to the water. The culture medium can be used to culture PRCs that are isolated from the body of a mammal to generate functional tissue-organs in vitro with substantially the same physiological structure and function as the corresponding ones existing in vivo and in situ. The cultured PRCs, tissues, and tissue-organs can serve as valuable models for scientific investigation in life sciences, nutraceutical discovery, drug screening, pharmacokinetic studies, medical devices and tissue / organ transplantation.

A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

Disclosed herein are methods for generating SC-β cells, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Disclosed herein are methods for generating SC-β cells, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

The present invention relates to differentiation of stem cells into a homogeneous endocrine progenitor cell population suitable for further differentiation into pancreatic beta-cells. The present invention provides methods for obtaining NGN3 / NKX2.2 double positive endocrine progenitor cells by exposing precursor cells to a TGF-β type I receptor inhibitor, a BMP antagonist, an adenylate cyclase activator and nicotinamide and / or exposing to the precursor cells to a selection of small molecules.

The present invention provides a method of obtaining aggregates containing a rostral hypothalamus tissue and a rostral head ectodermal tissue, a hypophysis precursor tissue and a hypophysis hormone producing cell, by using a serum-free medium (preferably substantially free of growth factor and insulins), forming homogeneous aggregates of stem cells from pluripotent stem cells such as ES cell and the like, which are plated at a high cell concentration, and subjecting the formed aggregates to floating-culture.

Embodiments herein relate in vitro methods of stem cell differentiation into thyroid hormone producing cells and tissues, and methods of use of these cells.

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method utilizing an agent that degrades retinoic acid to produce a population of pancreatic endocrine precursor cells.

Methods are provided for the establishment and maintenance in long term culture of hormone secreting cells. Cells are derived from tumorous or non-tumorous animal or human tissues, including ovary, endometrium, trophoblast, pituitary, thyroid, and pancreas. The cells secrete into the culture medium hormones such as estrogens, progestins, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotrophin, thyroxin, glucagon, and insulin, depending on the tissue of origin of individual cell cultures. Contact with an appropriate secretogogue causes the cells to respond with increased hormone secretion. For instance, ovarian follicular cells respond to follicle-stimulating hormone with increased estrogen and progesterone secretion. Pancreatic cells respond to elevated glucose with increased insulin secretion. The cells proliferate in in vitro for up to one year or longer, during which time they retain their hormone-secretion profile. The cells may be frozen for storage, and retain their hormone-secretion profile after thawing. The cell cultures are useful for the production of human hormones, for the bio-assay of drugs such as therapeutic gonadotrophin, for the testing of drug efficacy and design, and for toxicity testing of drugs and chemicals. The cells may also be implanted in an individual to replace deficient hormone secretion. For instance, insulin secreting pancreatic cells may be implanted in a diabetic individual as an adjunct or replacement therapy for exogenously administered insulin.

The invention relates to a method for culturing a dedifferentiated or undifferentiated thyroid carcinoma organ. The method comprises the following steps: mixing dedifferentiated or undifferentiated thyroid carcinoma tissue cells with a thyroid carcinoma culture medium and matrix glue to obtain a to-be-cultured substance, wherein the thyroid carcinoma culture medium contains nicotinamide and BM-Cyclin, and based on the thyroid carcinoma culture medium, the concentration of nicotinamide is 5-20 mM, and the concentration of BM-Cyclin is 5-30 [mu]g / ml; and carrying out culture amplification on theto-be-cultured substance to obtain the dedifferentiated or undifferentiated thyroid carcinoma organ. In the method for culturing the dedifferentiated or undifferentiated thyroid carcinoma organ, theadopted thyroid carcinoma culture medium contains nicotinamide and BM-Cyclin with specific concentrations, so that the in-vitro growth of the dedifferentiated or undifferentiated thyroid carcinoma organ is promoted. Therefore, when the method provided by the invention is used for culturing the dedifferentiated or undifferentiated thyroid carcinoma organ, the culture success rate is relatively high.

The present invention provides a reporter gene cell line and a construction method and an application thereof. A genome of the reporter gene cell line is integrated with a chimeric gene and the chimeric gene comprises an IFN-beta promoter and a reporter gene; and the report gene is a secreted luciferase gene. The constructed reporter gene cell strain can secrete luciferase outside cells, providesa simple means for detecting activation of an IFN pathway, and lays a foundation for a further study of virus-induced IFN-beta transcription and regulation, and dynamic monitoring of IFN-beta promoteractivity.

The invention discloses a three-dimensional tissue-like body of composite cells. By grafting small molecule compounds containing double bonds onto gelatin molecules with excellent biocompatibility tobuild gelatin DB-Gel modified by groups containing double bonds, a gelatin DB-Gel aqueous solution of a certain concentration is mixed with living cell (such as parathyroid gland cells) suspension, and through ultraviolet light curing, the three-dimensional tissue-like body of the composite cells is obtained. In the process of building the tissue-like body, DB-Gel is fully utilized as photo-polymerized hydrogel and has good bioactivity; by directly mixing the gelatin DB-Gel and the cells in a liquid state, the cells can be completely and uniformly dispersed in space, a three-dimensional growing environment closer to the internal environment is built for the cells, the efficiency of interaction between the cells and the external environment is improved in a three-dimensional cell culturingprocess, and compared with cells cultured in two dimensions, maintenance of cell forms and activity are both improved. A preparation method of the three-dimensional tissue-like body of the composite cells is simple, rapid and low in both equipment requirement and cost, and has great potential in internal and external research.

The invention provides a peptide to solve the problems of shorter plasma half-lives and lower activities of insulinotropic nascent peptides in the prior art. The peptide has a sequence as follows: Ac-IGLHDPTQGTEPAGE-OH (No.52), Ac-IGLHDPTQGTEPAG-NH2 (No.60), Ac-IGLHDPTQGTEPAGE-NH2 (No.62) or Ac-IGLHDPTQGTEPAGC-NH2 (No.72). Meanwhile, the invention also discloses peptide derivatives, medicinal salts of the peptide, a medicine composition and an application of the peptide and the peptide derivatives. The peptide provided by the invention has high stability and long half-life in blood.

The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.

The invention provides a method for separating and culturing pituitary gland cells of a rat. The method comprises steps as follows: (1), an 8d male SD rat is selected and subjected to anesthesia execution; (2), the anesthetized rat is fixed on a board with the ventral side facing upwards, the pituitary gland of the rat is taken out under the sterile condition, put in a pre-cooled PBS (poly(butylene succinate)) liquid and washed repeatedly, bloodstain is removed, and pituitary gland envelope is removed; (3), the pituitary gland is cut into 1 mm*1 mm fragments by ophthalmic scissors in the pre-cooled PBS liquid under the sterile condition; (4), pre-heated III type collagenase is combined with neutral enzyme for mixed digestion; (5), the digestion is stopped, filtering is performed, a filtrate is collected and centrifuged, a supernatant is abandoned, a culture medium is added for resuspension, and the operation is repeated three times; (6), a 24-hole culture plate is inoculated with cells for culture; (7), the cells cultured for 7d are subjected to trypsin digestion and then are purified by a screen again, a supernatant is abandoned after centrifugation, the cells are resuspended, and the treated culture plate is inoculated with the cells; (8), the cells are subjected to cell immunofluorescence identification. The method for separating and culturing the pituitary gland cells of the rat is simple to operate, the obtained pituitary gland cells are high in survival rate and good in activity, can be used for establishing a cell experimental model in vitro and meet the requirement of pituitary gland cell experiments.

The invention provides a polypeptide and aims to solve the problems of short half life of plasma and low activity of insulinotropic nascent polypeptides in the prior art. The polypeptide has a sequence of Ac-IGLHDPSHGTLPNGS-OH (No.16), Ac-IGLHDPSHGTLPNGS-NH2 (No.31) or Ac-IGLHDPSHGTLPNGSC-OH (No.34). In addition, the invention further discloses a derivative of the polypeptide, a pharmaceutical salt of the polypeptide, a pharmaceutical composition and application of the polypeptide or the derivative of the polypeptide. The polypeptide provided by the invention is highly stable in blood and has long half life.

The present application provides a method and kit for separating extracellular vesicles of tissue specific origin, and specifically, provides the method for separating the thyroid transcription factor1 positive extracellular vesicles, especially exosomes, from a biological fluid. The method includes the following steps: optionally separating total extracellular vesicles by a physical process, optionally removing extracellular vesicles derived from red blood cells and / or white blood cells by a binding agent, and positively capturing the extracellular vesicles or exosomes of target cells by using a binding agent binding to the thyroid transcription factor 1. The present application also provides an application of the binding agent binding to thyroid transcription factor 1 in preparation ofseparation or detection reagents of the extracellular vesicles or the exosomes, and the kit for separating the thyroid transcription factor positive extracellular vesicles or exosomes from the biological fluid.

The invention is directed to immunologically privileged cells, e.g., autologous, allogeneic, and xenogeneic intermediate lobe pituitary cells, for delivering polypeptides, e.g., insulin, to a subject, and to methods of using the same.

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells capable of producing insulin following transplantation into an animal.